Date: 2014-08-25
Type of information: Distribution agreement
Compound: Brinavess™ (vernakalant intravenous)
Company: Cardiome Pharma (Canada) Eurolab Especialidades Medicinales de Eurofar (Argentina)
Therapeutic area: Cardiovascular diseases
Type agreement: distribution
Action mechanism:
Disease: rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults for non-surgery patients with atrial fibrillation of seven days duration or less and for post-cardiac surgery patients with atrial fibrillation of three days duration or less
Details: * On August 25, 2014, Cardiome Pharma announced that its subsidiary, Correvio International Sàrl, has entered into an agreement with Eurolab Especialidades Medicinales de Eurofar S.R.L. to sell and distribute Brinavess™ (vernakalant intravenous) exclusively in Argentina. Under the terms of the agreement, Eurolab has agreed to specific annual commercial goals for Brinavess™. In 2010, the Argentine pharmaceutical market was valued at $5.1 billion with growth of 29.1% on a year-on-year basis.
Financial terms: Financial details of the agreement have not been disclosed.
Latest news:
